A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection

Trial Profile

A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs GEN 003 (Primary) ; Matrix M
  • Indications Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Sponsors Genocea Biosciences
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 08 Oct 2017 Results assessing immunogenicity responses to GEN-003 through 1 year of follow up presented at the IDWeek 2017
    • 28 Jul 2017 According to a Genocea Biosciences media release, data will be presented at the 42nd Annual International Herpesvirus Workshop 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top